tirzepatide wiki (LY3298176)|2023788-19-2|COA Tirzepatide (15mg Vial) - theragenetics
Description
Tirzepatide, under the brand name Mounjaro, is authorised for weight loss in adults who have a: BMI of 30 kg/m2 or above or a BMI of between 27 and 30 kg/m2 and have a weight-related health problem Tirzepatide is also recommended for people who have unmanaged blood sugar and type 2 diabetes, alongside diet and exercise changes
Secure from intake to delivery
You should report any sudden abdominal pain, fever, changes in bowel habits, or blood in stool immediately
Triggering insulin release When blood sugar levels rise after a meal, GLP-1 helps the pancreas release insulin, which lowers blood sugar by moving it into the bodys cells for energy
